Inactive Instrument
LYSOGENE Share Price
Stocks
LYS
FR0013233475
Biotechnology & Medical Research
OTC Markets Traded
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 09/05/2014 | |
| Director of Finance/CFO | - | 01/11/2022 | |
Marie Trad
CTO | Chief Tech/Sci/R&D Officer | - | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 54 | 22/05/2019 | |
Peter Lichtlen
BRD | Director/Board Member | 58 | 01/04/2018 |
Carole Deffez
BRD | Director/Board Member | - | 26/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 55.26L | |
| -0.22% | -2.26% | +139.07% | +102.52% | 461.84Cr | |
| +1.64% | +0.95% | +105.24% | +176.11% | 357.06Cr | |
| -0.77% | +10.09% | +29.22% | -33.12% | 229.06Cr | |
| -1.76% | -3.16% | -28.19% | -36.48% | 208.71Cr | |
| -0.45% | -6.77% | +186.66% | +253.81% | 194.29Cr | |
| -0.70% | -0.56% | +169.08% | -43.60% | 103.99Cr | |
| +2.42% | -3.50% | -8.01% | +28.14% | 85Cr | |
| +0.67% | -7.13% | -38.55% | -13.58% | 50Cr | |
| +6.72% | -9.36% | -4.60% | - | 43Cr | |
| Average | +0.76% | -1.34% | +61.10% | +54.23% | 192.58Cr | |
| Weighted average by Cap. | +0.18% | -0.06% | +88.66% | +83.76% |
Employees
22
